Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) is expected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Viridian Therapeutics to post earnings of ($1.05) per share and revenue of $0.05 million for the quarter.
Viridian Therapeutics Stock Performance
Shares of VRDN traded down $0.35 on Friday, reaching $16.27. 876,859 shares of the company's stock traded hands, compared to its average volume of 1,138,710. The stock has a market cap of $1.29 billion, a PE ratio of -3.77 and a beta of 1.32. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The stock's 50 day simple moving average is $18.63 and its two-hundred day simple moving average is $19.62. Viridian Therapeutics has a 52-week low of $11.40 and a 52-week high of $27.20.
Analyst Ratings Changes
Several equities analysts recently weighed in on VRDN shares. HC Wainwright restated a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a research report on Monday, December 16th. Royal Bank of Canada increased their target price on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the company an "outperform" rating in a research report on Tuesday, December 17th. Needham & Company LLC reaffirmed a "buy" rating and issued a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Wells Fargo & Company reissued an "equal weight" rating and set a $27.00 price objective (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Finally, TD Cowen initiated coverage on Viridian Therapeutics in a research note on Monday, November 25th. They issued a "buy" rating on the stock. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, Viridian Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $35.70.
Check Out Our Latest Stock Report on Viridian Therapeutics
About Viridian Therapeutics
(
Get Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Read More
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
